Related Experiment Videos
[THP-adriamycin in head and neck tumor]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 1, 1983
Summary
THP-adriamycin (THP-ADM) shows promise in treating head and neck cancers, with notable response rates in both carcinoma and lymphoma patients. This new agent appears to have milder side effects compared to standard Adriamycin.
Area of Science:
- Oncology
- Pharmacology
Background:
- Head and neck cancers present a significant therapeutic challenge.
- Anthracycline antineoplastic agents are crucial in cancer treatment.
Observation:
- A new anthracycline, THP-adriamycin (THP-ADM), was evaluated in 20 patients with malignant head and neck tumors.
- Patients had various tumor sites including oropharynx, nose, sinuses, tongue, floor of mouth, neck, and external auditory meatus.
- Tumor types included squamous cell carcinoma, malignant lymphoma, anaplastic carcinoma, carcinosarcoma, and adenoid cystic carcinoma.
Findings:
- THP-ADM demonstrated significant efficacy with objective response rates (CR, PR, MR) in both previously untreated and pretreated patients.
- Intra-arterial administration of THP-ADM yielded promising results, with 3 complete responses and 5 partial responses observed.
- Adverse effects, including leukopenia (WBC < 3000/mm3 in 9 cases), were generally less severe than those associated with standard Adriamycin.
Implications:
- THP-adriamycin represents a potentially effective and better-tolerated alternative for head and neck cancer treatment.
- Further clinical trials are warranted to establish the optimal use of THP-ADM in oncological practice.
- The findings suggest THP-ADM could improve patient outcomes and quality of life in head and neck oncology.